PPARα Modulation-Based Therapy in Central Nervous System Diseases
Abstract
:1. Introduction
2. Brain Diseases
3. Spinal Cord Diseases
4. Eye Diseases
5. Future Perspectives
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Daynes, R.A.; Jones, D.C. Emerging roles of PPARS in inflammation and immunity. Nat. Rev. Immunol. 2002, 2, 748–759. [Google Scholar] [CrossRef]
- Borel, V.; Gallot, D.; Marceau, G.; Sapin, V.; Blanchon, L. Placental Implications of Peroxisome Proliferator-Activated Receptors in Gestation and Parturition. PPAR Res. 2008, 2008, 758562. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fournier, T.; Tsatsaris, V.; Handschuh, K.; Evain-Brion, D. PPARs and the Placenta. Placenta 2007, 28, 65–76. [Google Scholar] [CrossRef]
- Nunez-Anita, R.E.; Cajero-Juarez, M.; Aceves, C. Peroxisome proliferator-activated receptors: Role of isoform gamma in the antineoplastic effect of iodine in mammary cancer. Curr. Cancer Drug Targets 2011, 11, 775–786. [Google Scholar] [CrossRef] [PubMed]
- Bright, J.J.; Kanakasabai, S.; Chearwae, W.; Chakraborty, S. PPAR Regulation of Inflammatory Signaling in CNS Diseases. PPAR Res. 2008, 2008, 658520. [Google Scholar] [CrossRef] [Green Version]
- Forman, B.M.; Chen, J.; Evans, R. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors and. Proc. Natl. Acad. Sci. USA 1997, 94, 4312–4317. [Google Scholar] [CrossRef] [Green Version]
- Kliewer, S.A.; Sundseth, S.S.; Jones, S.A.; Brown, P.; Wisely, G.B.; Koble, C.S.; Devchand, P.; Wahli, W.; Willson, T.M.; Lenhard, J.M.; et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors and. Proc. Natl. Acad. Sci. USA 1997, 94, 4318–4323. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Krey, G.; Braissant, O.; L’Horset, F.; Kalkhoven, E.; Perroud, M.; Parker, M.G.; Wahli, W. Fatty Acids, Eicosanoids, and Hypolipidemic Agents Identified as Ligands of Peroxisome Proliferator-Activated Receptors by Coactivator-Dependent Receptor Ligand Assay. Mol. Endocrinol. 1997, 11, 779–791. [Google Scholar] [CrossRef]
- Yu, K.; Bayona, W.; Kallen, C.; Harding, H.; Ravera, C.P.; McMahon, G.; Brown, M.; Lazar, M.A. Differential Activation of Peroxisome Proliferator-activated Receptors by Eicosanoids. J. Biol. Chem. 1995, 270, 23975–23983. [Google Scholar] [CrossRef] [Green Version]
- Chakravarthy, M.V.; Lodhi, I.J.; Yin, L.; Malapaka, R.R.; Xu, H.E.; Turk, J.; Semenkovich, C.F. Identification of a Physiologically Relevant Endogenous Ligand for PPARα in Liver. Cell 2009, 138, 476–488. [Google Scholar] [CrossRef] [Green Version]
- Tyagi, S.; Sharma, S.; Gupta, P.; Saini, A.S.; Kaushal, C. The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases. J. Adv. Pharm. Technol. Res. 2011, 2, 236–240. [Google Scholar] [CrossRef]
- Zolezzi, J.M.; Santos, M.J.; Bastías-Candia, S.; Pinto, C.; Godoy, J.A.; Inestrosa, N.C. PPARs in the central nervous system: Roles in neurodegeneration and neuroinflammation. Biol. Rev. 2017, 92, 2046–2069. [Google Scholar] [CrossRef]
- Villapol, S. Roles of Peroxisome Proliferator-Activated Receptor Gamma on Brain and Peripheral Inflammation. Cell. Mol. Neurobiol. 2017, 38, 121–132. [Google Scholar] [CrossRef] [PubMed]
- Landreth, G.; Jiang, Q.; Mandrekar, S.; Heneka, M. PPARγ agonists as therapeutics for the treatment of Alzheimer’s disease. Neurotherapeutics 2008, 5, 481–489. [Google Scholar] [CrossRef] [Green Version]
- Wójtowicz, S.; Strosznajder, J.B.; Jeżyna, M. The Novel Role of PPAR Alpha in the Brain: Promising Target in Therapy of Alzheimer’s Disease and Other Neurodegenerative Disorders. Neurochem. Res. 2020, 45, 972–988. [Google Scholar] [CrossRef] [Green Version]
- Paterniti, I.; Campolo, M.; Cordaro, M.; Impellizzeri, D.; Siracusa, R.; Crupi, R.; Esposito, E.; Cuzzocrea, S. PPAR-α Modulates the Anti-Inflammatory Effect of Melatonin in the Secondary Events of Spinal Cord Injury. Mol. Neurobiol. 2016, 54, 5973–5987. [Google Scholar] [CrossRef]
- Tomita, Y.; Lee, D.; Tsubota, K.; Kurihara, T. PPARα Agonist Oral Therapy in Diabetic Retinopathy. Biomedicines 2020, 8, 433. [Google Scholar] [CrossRef]
- Warden, A.; Truitt, J.; Merriman, M.; Ponomareva, O.; Jameson, K.; Ferguson, L.B.; Mayfield, R.D.; Harris, R.A. Localization of PPAR isotypes in the adult mouse and human brain. Sci. Rep. 2016, 6, 27618. [Google Scholar] [CrossRef] [PubMed]
- Corbett, G.T.; Gonzalez, F.J.; Pahan, K. Activation of peroxisome proliferator-activated receptor α stimulates ADAM10-mediated proteolysis of APP. Proc. Natl. Acad. Sci. USA 2015, 112, 8445–8450. [Google Scholar] [CrossRef] [Green Version]
- Yuan, X.-Z.; Sun, S.; Tan, C.-C.; Yu, J.-T.; Tan, L. The Role of ADAM10 in Alzheimer’s Disease. J. Alzheimers Dis. 2017, 58, 303–322. [Google Scholar] [CrossRef] [PubMed]
- Kuhn, P.-H.; Wang, H.; Dislich, B.; Colombo, A.; Zeitschel, U.; Ellwart, J.W.; Kremmer, E.; Rossner, S.; Lichtenthaler, S.F. ADAM10 is the physiologically relevant, constitutive α-secretase of the amyloid precursor protein in primary neurons. EMBO J. 2010, 29, 3020–3032. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Postina, R.; Schroeder, A.; Dewachter, I.; Bohl, J.; Schmitt, U.; Kojro, E.; Prinzen, C.; Endres, K.; Hiemke, C.; Blessing, M.; et al. A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J. Clin. Investig. 2004, 113, 1456–1464. [Google Scholar] [CrossRef] [Green Version]
- Santos, M.J.; Quintanilla, R.A.; Toro, A.; Grandy, R.; Dinamarca, M.C.; Godoy, A.J.; Inestrosa, N.C. Peroxisomal Proliferation Protects from β-Amyloid Neurodegeneration. J. Biol. Chem. 2005, 280, 41057–41068. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Katsumoto, A.; Takeuchi, H.; Tanaka, F. Tau Pathology in Chronic Traumatic Encephalopathy and Alzheimer’s Disease: Similarities and Differences. Front. Neurol. 2019, 10, 980. [Google Scholar] [CrossRef] [PubMed]
- Trojanowski, J.Q.; Lee, V.M. Phosphorylation of paired helical filament tau in Alzheimer’s disease neurofibrillary lesions: Focusing on phosphatases. FASEB J. 1995, 9, 1570–1576. [Google Scholar] [CrossRef]
- Inestrosa, N.C.; Carvajal, F.J.; Zolezzi, J.M.; Tapia-Rojas, C.; Serrano, F.; Karmelic, D.; Toledo, E.M.; Toro, A.; Toro, J.; Santos, M.J. Peroxisome Proliferators Reduce Spatial Memory Impairment, Synaptic Failure, and Neurodegeneration in Brains of a Double Transgenic Mice Model of Alzheimer’s Disease. J. Alzheimers Dis. 2013, 33, 941–959. [Google Scholar] [CrossRef] [Green Version]
- Zhang, H.; Gao, Y.; Qiao, P.; Zhao, F.; Yan, Y. Fenofibrate reduces amyloidogenic processing of APP in APP/PS1 transgenic mice via PPAR-α/PI3-K pathway. Int. J. Dev. Neurosci. 2014, 38, 223–231. [Google Scholar] [CrossRef]
- Chang, J.; Rimando, A.; Pallas, M.; Camins, A.; Porquet, D.; Reeves, J.; Shukitt-Hale, B.; Smith, M.A.; Joseph, J.A.; Casadesus, G. Low-dose pterostilbene, but not resveratrol, is a potent neuromodulator in aging and Alzheimer’s disease. Neurobiol. Aging 2012, 33, 2062–2071. [Google Scholar] [CrossRef]
- Wada, Y.; Maekawa, M.; Ohnishi, T.; Balan, S.; Matsuoka, S.; Iwamoto, K.; Iwayama, Y.; Ohba, H.; Watanabe, A.; Hisano, Y.; et al. Peroxisome proliferator-activated receptor α as a novel therapeutic target for schizophrenia. EBioMedicine 2020, 62, 103130. [Google Scholar] [CrossRef]
- Jiang, B.; Huang, C.; Zhu, Q.; Tong, L.-J.; Zhang, W. WY14643 produces anti-depressant-like effects in mice via the BDNF signaling pathway. Psychopharmacology 2014, 232, 1629–1642. [Google Scholar] [CrossRef] [PubMed]
- Björkholm, C.; Monteggia, L.M. BDNF—a key transducer of antidepressant effects. Neuropharmacology 2015, 102, 72–79. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Locci, A.; Pinna, G. Stimulation of Peroxisome Proliferator-Activated Receptor-α by N-Palmitoylethanolamine Engages Allopregnanolone Biosynthesis to Modulate Emotional Behavior. Biol. Psychiatry 2019, 85, 1036–1045. [Google Scholar] [CrossRef] [PubMed]
- Esposito, E.; Impellizzeri, D.; Mazzon, E.; Paterniti, I.; Cuzzocrea, S. Neuroprotective Activities of Palmitoylethanolamide in an Animal Model of Parkinson’s Disease. PLoS ONE 2012, 7, e41880. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kreisler, A.; Gelé, P.; Wiart, J.-F.; Lhermitte, M.; Destée, A.; Bordet, R. Lipid-lowering drugs in the MPTP mouse model of Parkinson’s disease: Fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not. Brain Res. 2007, 1135, 77–84. [Google Scholar] [CrossRef] [PubMed]
- Obrador, E.; Salvador, R.; López-Blanch, R.; Jihad-Jebbar, A.; Vallés, S.L.; Estrela, J.M. Oxidative Stress, Neuroinflammation and Mitochondria in the Pathophysiology of Amyotrophic Lateral Sclerosis. Antioxidants 2020, 9, 901. [Google Scholar] [CrossRef]
- Liu, J.; Wang, F. Role of Neuroinflammation in Amyotrophic Lateral Sclerosis: Cellular Mechanisms and Therapeutic Implications. Front. Immunol. 2017, 8, 1005. [Google Scholar] [CrossRef] [Green Version]
- Sassone, J.; Taiana, M.; Lombardi, R.; Porretta-Serapiglia, C.; Freschi, M.; Bonanno, S.; Marcuzzo, S.; Caravello, F.; Bendotti, C.; Lauria, G. ALS mouse model SOD1G93Adisplays early pathology of sensory small fibers associated to accumulation of a neurotoxic splice variant of peripherin. Hum. Mol. Genet. 2016, 25, 1588–1599. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Esmaeili, M.A.; Yadav, S.; Gupta, R.K.; Waggoner, G.R.; Deloach, A.; Calingasan, N.Y.; Beal, M.F.; Kiaei, M. Preferential PPAR-α activation reduces neuroinflammation, and blocks neurodegenerationin vivo. Hum. Mol. Genet. 2015, 25, 317–327. [Google Scholar] [CrossRef] [Green Version]
- Compston, A.; Coles, A. Multiple sclerosis. Lancet 2008, 372, 1502–1517. [Google Scholar] [CrossRef]
- Goverman, J. Autoimmune T cell responses in the central nervous system. Nat. Rev. Immunol. 2009, 9, 393–407. [Google Scholar] [CrossRef] [Green Version]
- McGinley, M.P.; Goldschmidt, C.H.; Rae-Grant, A.D. Diagnosis and Treatment of Multiple Sclerosis. JAMA 2021, 325, 765–779. [Google Scholar] [CrossRef] [PubMed]
- Lovett-Racke, A.E.; Hussain, R.Z.; Northrop, S.; Choy, J.; Rocchini, A.; Matthes, L.; Chavis, J.A.; Diab, A.; Drew, P.D.; Racke, M.K. Peroxisome Proliferator-Activated Receptor α Agonists as Therapy for Autoimmune Disease. J. Immunol. 2004, 172, 5790–5798. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yang, Y.; Gocke, A.R.; Lovett-Racke, A.; Drew, P.D.; Racke, M.K. PPAR Alpha Regulation of the Immune Response and Autoimmune Encephalomyelitis. PPAR Res. 2008, 2008, 546753. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Constantinescu, C.S.; Farooqi, N.; O’Brien, K.; Gran, B. Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br. J. Pharmacol. 2011, 164, 1079–1106. [Google Scholar] [CrossRef]
- Dunn, S.E.; Ousman, S.S.; Sobel, R.A.; Zuniga, L.; Baranzini, S.E.; Youssef, S.; Crowell, A.; Loh, J.; Oksenberg, J.; Steinman, L. Peroxisome proliferator–activated receptor (PPAR)α expression in T cells mediates gender differences in development of T cell–mediated autoimmunity. J. Exp. Med. 2007, 204, 321–330. [Google Scholar] [CrossRef] [Green Version]
- Harbo, H.F.; Gold, R.; Tintore, M. Sex and gender issues in multiple sclerosis. Ther. Adv. Neurol. Disord. 2013, 6, 237–248. [Google Scholar] [CrossRef] [Green Version]
- Xu, J.; Racke, M.K.; Drew, P.D. Peroxisome proliferator-activated receptor-α agonist fenofibrate regulates IL-12 family cytokine expression in the CNS: Relevance to multiple sclerosis. J. Neurochem. 2007, 103, 1801–1810. [Google Scholar] [CrossRef] [Green Version]
- Xu, J.; Chavis, J.A.; Racke, M.K.; Drew, P.D. Peroxisome proliferator-activated receptor-α and retinoid X receptor agonists inhibit inflammatory responses of astrocytes. J. Neuroimmunol. 2006, 176, 95–105. [Google Scholar] [CrossRef]
- Sun, L.; He, C.; Nair, L.; Yeung, J.; Egwuagu, C.E. Interleukin 12 (IL-12) family cytokines: Role in immune pathogenesis and treatment of CNS autoimmune disease. Cytokine 2015, 75, 249–255. [Google Scholar] [CrossRef] [Green Version]
- Aloisi, F.; Penna, G.; Cerase, J.; Iglesias, B.M.; Adorini, L. IL-12 production by central nervous system microglia is inhibited by astrocytes. J. Immunol. 1997, 159, 1604–1612. [Google Scholar]
- Trinchieri, G.; Pflanz, S.; Kastelein, A.R. The IL-12 Family of Heterodimeric Cytokines. Immunity 2003, 19, 641–644. [Google Scholar] [CrossRef] [Green Version]
- Robinson, D.S.; O’Garra, A. Further Checkpoints in Th1 Development. Immunity 2002, 16, 755–758. [Google Scholar] [CrossRef] [Green Version]
- Gautier, S.; Ouk, T.; Petrault, M.; Pétrault, O.; Berezowski, V.; Bordet, R. PPAR-Alpha Agonist Used at the Acute Phase of Experimental Ischemic Stroke Reduces Occurrence of Thrombolysis-Induced Hemorrhage in Rats. PPAR Res. 2015, 2015, 246329. [Google Scholar] [CrossRef]
- Guo, Q.; Wang, G.; Namura, S. Fenofibrate Improves Cerebral Blood Flow after Middle Cerebral Artery Occlusion in Mice. Br. J. Pharmacol. 2009, 30, 70–78. [Google Scholar] [CrossRef] [Green Version]
- Schomacher, M.; Müller, H.D.; Sommer, C.; Schwab, S.; Schäbitz, W.-R. Endocannabinoids mediate neuroprotection after transient focal cerebral ischemia. Brain Res. 2008, 1240, 213–220. [Google Scholar] [CrossRef]
- Ahmad, A.; Genovese, T.; Impellizzeri, D.; Crupi, R.; Velardi, E.; Marino, A.; Esposito, E.; Cuzzocrea, S. Reduction of ischemic brain injury by administration of palmitoylethanolamide after transient middle cerebral artery occlusion in rats. Brain Res. 2012, 1477, 45–58. [Google Scholar] [CrossRef] [PubMed]
- Moreno, S.; Vecchioli, S.F.; Cerù, M. Immunolocalization of peroxisome proliferator-activated receptors and retinoid x receptors in the adult rat CNS. Neuroscience 2003, 123, 131–145. [Google Scholar] [CrossRef] [PubMed]
- Benani, A.; Krémarik-Bouillaud, P.; Bianchi, A.; Netter, P.; Minn, A.; Dauça, M. Evidence for the presence of both peroxisome proliferator-activated receptors alpha and beta in the rat spinal cord. J. Chem. Neuroanat. 2002, 25, 29–38. [Google Scholar] [CrossRef]
- Benani, A.; Heurtaux, T.; Netter, P.; Minn, A. Activation of peroxisome proliferator-activated receptor alpha in rat spinal cord after peripheral noxious stimulation. Neurosci. Lett. 2004, 369, 59–63. [Google Scholar] [CrossRef]
- Esposito, E.; Rinaldi, B.; Mazzon, E.; Donniacuo, M.; Impellizzeri, D.; Paterniti, I.; Capuano, A.; Bramanti, P.; Cuzzocrea, S. Anti-inflammatory effect of simvastatin in an experimental model of spinal cord trauma: Involvement of PPAR-α. J. Neuroinflamm. 2012, 9, 81. [Google Scholar] [CrossRef] [Green Version]
- Genovese, T.; Esposito, E.; Mazzon, E.; Crisafulli, C.; Paterniti, I.; Di Paola, R.; Galuppo, M.; Bramanti, P.; Cuzzocrea, S. PPAR-α modulate the anti-inflammatory effect of glucocorticoids in the secondary damage in experimental spinal cord trauma. Pharmacol. Res. 2009, 59, 338–350. [Google Scholar] [CrossRef] [PubMed]
- Almad, A.; Lash, A.T.; Wei, P.; Lovett-Racke, A.E.; McTigue, D.M. The PPAR alpha agonist gemfibrozil is an ineffective treatment for spinal cord injured mice. Exp. Neurol. 2011, 232, 309–317. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Herzlich, A.A.; Ding, X.; Shen, D.; Ross, R.J.; Tuo, J.; Chan, C.-C. Peroxisome Proliferator-Activated Receptor Expression in Murine Models and Humans with Age-related Macular Degeneration. Open Biol. J. 2009, 2, 141–148. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, J.-Z.; Ward, K.W. WY-14 643, a Selective PPARα Agonist, Induces Proinflammatory and Proangiogenic Responses in Human Ocular Cells. Int. J. Toxicol. 2010, 29, 496–504. [Google Scholar] [CrossRef] [PubMed]
- Tang, L.; Wang, X.; Wu, J.; Li, S.M.; Zhang, Z.; Wu, S.; Su, T.; Lin, Z.; Chen, X.; Liao, X.; et al. Sleep Deprivation Induces Dry Eye Through Inhibition of PPARα Expression in Corneal Epithelium. Investig. Opthalmology Vis. Sci. 2018, 59, 5494–5508. [Google Scholar] [CrossRef] [Green Version]
- Escandon, P.; Vasini, B.; Whelchel, A.E.; Nicholas, S.E.; Matlock, H.G.; Ma, J.-X.; Karamichos, D. The role of peroxisome proliferator-activated receptors in healthy and diseased eyes. Exp. Eye Res. 2021, 208, 108617. [Google Scholar] [CrossRef]
- Keech, A.C.; Simes, R.J.; Barter, P.J.; Best, J.; Scott, R.A.P.; Taskinen, M.-R.; Forder, P.M.; Pillai, A.; Davis, T.M.; Glasziou, P.; et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 2005, 366, 1849–1861. [Google Scholar] [CrossRef]
- Chew, E.Y.; Davis, M.D.; Danis, R.P.; Lovato, J.F.; Perdue, L.H.; Greven, C.; Genuth, S.; Goff, D.C.; Leiter, L.A.; Ismail-Beigi, F.; et al. The Effects of Medical Management on the Progression of Diabetic Retinopathy in Persons with Type 2 Diabetes. Ophthalmology 2014, 121, 2443–2451. [Google Scholar] [CrossRef] [Green Version]
- Chen, Y.; Hu, Y.; Lin, M.; Jenkins, A.J.; Keech, A.C.; Mott, R.; Lyons, T.J.; Ma, J.-X. Therapeutic Effects of PPARα Agonists on Diabetic Retinopathy in Type 1 Diabetes Models. Diabetes 2012, 62, 261–272. [Google Scholar] [CrossRef] [Green Version]
- Pearsall, E.; Cheng, R.; Matsuzaki, S.; Zhou, K.; Ding, L.; Ahn, B.; Kinter, M.; Humphries, K.M.; Quiambao, A.B.; Farjo, R.A.; et al. Neuroprotective effects of PPARα in retinopathy of type 1 diabetes. PLoS ONE 2019, 14, e0208399. [Google Scholar] [CrossRef] [Green Version]
- Tomita, Y.; Lee, D.; Tsubota, K.; Negishi, K.; Kurihara, T. Updates on the Current Treatments for Diabetic Retinopathy and Possibility of Future Oral Therapy. J. Clin. Med. 2021, 10, 4666. [Google Scholar] [CrossRef] [PubMed]
- Beltramo, E. Pericyte Loss in Diabetic Retinopathy: Mechanisms and Consequences. Curr. Med. Chem. 2013, 20, 3218–3225. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Engerman, R.L. Pathogenesis of Diabetic Retinopathy. Diabetes 1989, 38, 1203–1206. [Google Scholar] [CrossRef] [PubMed]
- Ding, L.; Cheng, R.; Hu, Y.; Takahashi, Y.; Jenkins, A.; Keech, A.C.; Humphries, K.; Gu, X.; Elliott, M.H.; Xia, X.; et al. Peroxisome Proliferator–Activated Receptor α Protects Capillary Pericytes in the Retina. Am. J. Pathol. 2014, 184, 2709–2720. [Google Scholar] [CrossRef] [Green Version]
- Yamazaki, Y.; Abe, K.; Toma, T.; Nishikawa, M.; Ozawa, H.; Okuda, A.; Araki, T.; Oda, S.; Inoue, K.; Shibuya, K.; et al. Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor α agonists. Bioorganic Med. Chem. Lett. 2007, 17, 4689–4693. [Google Scholar] [CrossRef]
- Fruchart, J.-C. Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists. Cardiovasc. Diabetol. 2013, 12, 82. [Google Scholar] [CrossRef] [Green Version]
- Fruchart, J.-C. Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia. Cardiovasc. Diabetol. 2017, 16, 1–12. [Google Scholar] [CrossRef]
- Raza-Iqbal, S.; Tanaka, T.; Anai, M.; Inagaki, T.; Matsumura, Y.; Ikeda, K.; Taguchi, A.; Gonzalez, F.J.; Sakai, J.; Kodama, T. Transcriptome Analysis of K-877 (a Novel Selective PPARα Modulator (SPPARMα))-Regulated Genes in Primary Human Hepatocytes and the Mouse Liver. J. Atheroscler. Thromb. 2015, 22, 754–772. [Google Scholar] [CrossRef] [Green Version]
- Kostapanos, M.; Florentin, M.; Elisaf, M.S. Fenofibrate and the kidney: An overview. Eur. J. Clin. Investig. 2013, 43, 522–531. [Google Scholar] [CrossRef]
- Shiono, A.; Sasaki, H.; Sekine, R.; Abe, Y.; Matsumura, Y.; Inagaki, T.; Tanaka, T.; Kodama, T.; Aburatani, H.; Sakai, J.; et al. PPARα activation directly upregulates thrombomodulin in the diabetic retina. Sci. Rep. 2020, 10, 1–12. [Google Scholar] [CrossRef]
- Boffa, M.C.; Burke, B.; Haudenschild, C.C. Preservation of thrombomodulin antigen on vascular and extravascular surfaces. J. Histochem. Cytochem. 1987, 35, 1267–1276. [Google Scholar] [CrossRef] [Green Version]
- Myles, T.; Nishimura, T.; Yun, T.H.; Nagashima, M.; Morser, J.; Patterson, A.J.; Pearl, R.G.; Leung, L.L. Thrombin Activatable Fibrinolysis Inhibitor, a Potential Regulator of Vascular Inflammation. J. Biol. Chem. 2003, 278, 51059–51067. [Google Scholar] [CrossRef] [Green Version]
- Conway, E.M. Thrombomodulin and its role in inflammation. Semin. Immunopathol. 2011, 34, 107–125. [Google Scholar] [CrossRef]
- Lieth, E.; Barber, A.; Xu, B.; Dice, C.; Ratz, M.J.; Tanase, D.; Strother, J.M. Glial reactivity and impaired glutamate metabolism in short-term experimental diabetic retinopathy. Penn State Retina Research Group. Diabetes 1998, 47, 815–820. [Google Scholar] [CrossRef] [PubMed]
- Ambati, J. Elevated γ-Aminobutyric Acid, Glutamate, and Vascular Endothelial Growth Factor Levels in the Vitreous of Patients with Proliferative Diabetic Retinopathy. Arch. Ophthalmol. 1997, 115, 1161–1166. [Google Scholar] [CrossRef] [PubMed]
- Gowda, K.; Zinnanti, W.J.; LaNoue, K.F. The influence of diabetes on glutamate metabolism in retinas. J. Neurochem. 2011, 117, 309–320. [Google Scholar] [CrossRef]
- Fujita, N.; Sase, K.; Tsukahara, C.; Arizono, I.; Takagi, H.; Kitaoka, Y. Pemafibrate prevents retinal neuronal cell death in NMDA-induced excitotoxicity via inhibition of p-c-Jun expression. Mol. Biol. Rep. 2020, 48, 195–202. [Google Scholar] [CrossRef] [PubMed]
- Oshitari, T.; Bikbova, G.; Yamamoto, S. Increased expression of phosphorylated c-Jun and phosphorylated c-Jun N-terminal kinase associated with neuronal cell death in diabetic and high glucose exposed rat retinas. Brain Res. Bull. 2013, 101, 18–25. [Google Scholar] [CrossRef]
- Tomita, Y.; Lee, D.; Miwa, Y.; Jiang, X.; Ohta, M.; Tsubota, K.; Kurihara, T. Pemafibrate Protects Against Retinal Dysfunction in a Murine Model of Diabetic Retinopathy. Int. J. Mol. Sci. 2020, 21, 6243. [Google Scholar] [CrossRef]
- Tomita, Y.; Ozawa, N.; Miwa, Y.; Ishida, A.; Ohta, M.; Tsubota, K.; Kurihara, T. Pemafibrate Prevents Retinal Pathological Neovascularization by Increasing FGF21 Level in a Murine Oxygen-Induced Retinopathy Model. Int. J. Mol. Sci. 2019, 20, 5878. [Google Scholar] [CrossRef] [Green Version]
- Tezze, C.; Romanello, V.; Sandri, M. FGF21 as Modulator of Metabolism in Health and Disease. Front. Physiol. 2019, 10, 419. [Google Scholar] [CrossRef]
- Fu, Z.; Gong, Y.; Liegl, R.; Wang, Z.; Liu, C.-H.; Meng, S.S.; Burnim, S.B.; Saba, N.J.; Fredrick, T.W.; Morss, P.C.; et al. FGF21 Administration Suppresses Retinal and Choroidal Neovascularization in Mice. Cell Rep. 2017, 18, 1606–1613. [Google Scholar] [CrossRef] [PubMed]
- Tomita, Y.; Fu, Z.; Wang, Z.; Cakir, B.; Cho, S.S.; Britton, W.; Sun, Y.; Hellström, A.; Talukdar, S.; Smith, L.E. Long-Acting FGF21 Inhibits Retinal Vascular Leakage in In Vivo and In Vitro Models. Int. J. Mol. Sci. 2020, 21, 1188. [Google Scholar] [CrossRef] [Green Version]
- Enright, J.M.; Zhang, S.; Thebeau, C.; Siebert, E.; Jin, A.; Gadiraju, V.; Zhang, X.; Chen, S.; Semenkovich, C.F.; Rajagopal, R. Fenofibrate Reduces the Severity of Neuroretinopathy in a Type 2 Model of Diabetes without Inducing Peroxisome Proliferator-Activated Receptor Alpha-Dependent Retinal Gene Expression. J. Clin. Med. 2020, 10, 126. [Google Scholar] [CrossRef]
- Qiu, F.; Matlock, G.; Chen, Q.; Zhou, K.; Du, Y.; Wang, X.; Ma, J.-X. Therapeutic Effects of PPARα Agonist on Ocular Neovascularization in Models Recapitulating Neovascular Age-Related Macular Degeneration. Investig. Opthalmol. Vis. Sci. 2017, 58, 5065–5075. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chen, Q.; Jiang, N.; Zhang, Y.; Ye, S.; Liang, X.; Wang, X.; Lin, X.; Zong, R.; Chen, H.; Liu, Z. Fenofibrate Inhibits Subretinal Fibrosis Through Suppressing TGF-β—Smad2/3 signaling and Wnt signaling in Neovascular Age-Related Macular Degeneration. Front. Pharmacol. 2020, 11, 580884. [Google Scholar] [CrossRef] [PubMed]
- Mandala, A.; Armstrong, A.; Girresch, B.; Zhu, J.; Chilakala, A.; Chavalmane, S.; Chaudhary, K.; Biswas, P.; Ogilvie, J.; Gnana-Prakasam, J.P. Fenofibrate prevents iron induced activation of canonical Wnt/β-catenin and oxidative stress signaling in the retina. Npj Aging Mech. Dis. 2020, 6, 1–11. [Google Scholar] [CrossRef]
- Beatty, S.; Koh, H.-H.; Phil, M.; Henson, D.; Boulton, M. The Role of Oxidative Stress in the Pathogenesis of Age-Related Macular Degeneration. Surv. Ophthalmol. 2000, 45, 115–134. [Google Scholar] [CrossRef] [Green Version]
- Dentchev, T.; Hahn, P.; Dunaief, J.L. Strong Labeling for Iron and the Iron-Handling Proteins Ferritin and Ferroportin in the Photoreceptor Layer in Age-Related Macular Degeneration. Arch. Ophthalmol. 2005, 123, 1745–1746. [Google Scholar] [CrossRef] [Green Version]
- Sur, A.; Kesaraju, S.; Prentice, H.; Ayyanathan, K.; Baronas-Lowell, D.; Zhu, D.; Hinton, D.R.; Blanks, J.; Weissbach, H. Pharmacological protection of retinal pigmented epithelial cells by sulindac involves PPAR-α. Proc. Natl. Acad. Sci. USA 2014, 111, 16754–16759. [Google Scholar] [CrossRef] [Green Version]
- Lee, D.; Tomita, Y.; Miwa, Y.; Jeong, H.; Mori, K.; Tsubota, K.; Kurihara, T. Fenofibrate Protects against Retinal Dysfunction in a Murine Model of Common Carotid Artery Occlusion-Induced Ocular Ischemia. Pharmaceuticals 2021, 14, 223. [Google Scholar] [CrossRef]
- Lee, D.; Tomita, Y.; Jeong, H.; Miwa, Y.; Tsubota, K.; Negishi, K.; Kurihara, T. Pemafibrate Prevents Retinal Dysfunction in a Mouse Model of Unilateral Common Carotid Artery Occlusion. Int. J. Mol. Sci. 2021, 22, 9408. [Google Scholar] [CrossRef]
- Bonora, B.M.; Albiero, M.; Morieri, M.L.; Cappellari, R.; Amendolagine, F.I.; Mazzucato, M.; Zambon, A.; Iori, E.; Avogaro, A.; Fadini, G.P. Fenofibrate increases circulating haematopoietic stem cells in people with diabetic retinopathy: A randomised, placebo-controlled trial. Diabetologia 2021, 64, 2334–2344. [Google Scholar] [CrossRef]
- Matlock, H.G.; Qiu, F.; Malechka, V.; Zhou, K.; Cheng, R.; Benyajati, S.; Whelchel, A.; Karamichos, D.; Ma, J.-X. Pathogenic Role of PPARα Downregulation in Corneal Nerve Degeneration and Impaired Corneal Sensitivity in Diabetes. Diabetes 2020, 69, 1279–1291. [Google Scholar] [CrossRef]
- Arima, T.; Uchiyama, M.; Nakano, Y.; Nagasaka, S.; Kang, D.; Shimizu, A.; Takahashi, H. Peroxisome proliferator-activated receptor alpha agonist suppresses neovascularization by reducing both vascular endothelial growth factor and angiopoietin-2 in corneal alkali burn. Sci. Rep. 2017, 7, 1–11. [Google Scholar] [CrossRef]
- Nakano, Y.; Arima, T.; Tobita, Y.; Uchiyama, M.; Shimizu, A.; Takahashi, H. Combination of Peroxisome Proliferator-Activated Receptor (PPAR) Alpha and Gamma Agonists Prevents Corneal Inflammation and Neovascularization in a Rat Alkali Burn Model. Int. J. Mol. Sci. 2020, 21, 5093. [Google Scholar] [CrossRef]
- Panigrahy, D.; Kaipainen, A.; Huang, S.; Butterfield, C.E.; Barnés, C.M.; Fannon, M.; Laforme, A.M.; Chaponis, D.M.; Folkman, J.; Kieran, M.W. PPAR agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc. Natl. Acad. Sci. USA 2008, 105, 985–990. [Google Scholar] [CrossRef] [Green Version]
- Bordet, R.; Ouk, T.; Petrault, O.; Gelé, P.; Gautier, S.; Laprais, M.; Deplanque, D.; Duriez, P.; Staels, B.; Fruchart, J.C.; et al. PPAR: A new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem. Soc. Trans. 2006, 34, 1341–1346. [Google Scholar] [CrossRef] [Green Version]
- Panlilio, L.V.; Justinova, Z.; Mascia, P.; Pistis, M.; Luchicchi, A.; Lecca, S.; Barnes, C.; Redhi, G.H.; Adair, J.; Heishman, S.J.; et al. Novel Use of a Lipid-Lowering Fibrate Medication to Prevent Nicotine Reward and Relapse: Preclinical Findings. Neuropsychopharmacology 2012, 37, 1838–1847. [Google Scholar] [CrossRef] [Green Version]
- Fidaleo, M.; Fanelli, F.; Ceru, M.P.; Moreno, S. Neuroprotective properties of peroxisome proliferator-activated receptor alpha (PPAR?) and its lipid ligands. Curr. Med. Chem. 2014, 21, 2803–2821. [Google Scholar] [CrossRef]
- Nisbett, K.E.; Pinna, G. Emerging Therapeutic Role of PPAR–α in Cognition and Emotions. Front. Pharmacol. 2018, 9, 998. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Lee, D.; Tomita, Y.; Allen, W.; Tsubota, K.; Negishi, K.; Kurihara, T. PPARα Modulation-Based Therapy in Central Nervous System Diseases. Life 2021, 11, 1168. https://doi.org/10.3390/life11111168
Lee D, Tomita Y, Allen W, Tsubota K, Negishi K, Kurihara T. PPARα Modulation-Based Therapy in Central Nervous System Diseases. Life. 2021; 11(11):1168. https://doi.org/10.3390/life11111168
Chicago/Turabian StyleLee, Deokho, Yohei Tomita, William Allen, Kazuo Tsubota, Kazuno Negishi, and Toshihide Kurihara. 2021. "PPARα Modulation-Based Therapy in Central Nervous System Diseases" Life 11, no. 11: 1168. https://doi.org/10.3390/life11111168